HH Wong, C Parkinson, JA Ledermann, JD Brenton, M Merger, A Shaw, A Patterson, M Shafi, HM Earl
Gynecol Oncol Case Rep
► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.